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Abstract: Pneumonia, an inflammatory infiltrate of the alveolar airspace, is commonly triggered by 
bacterial infection of the lungs, or less commonly by viral or fungal infection. It remains the commonest 
infective reason for admission to intensive care as well as being the most common secondary infection 
acquired whilst in the intensive care unit (ICU). It presents a significant global burden of disease and is 
especially prevalent in low- and middle-income countries. The major categories of pneumonia encountered 
by the Intensive Care clinician are community-acquired, ventilator-acquired, non-ventilator hospital-
acquired and pneumonia in the immunocompromised patient. An appreciation of the type of pneumonia a 
patient has developed is critical to its effective treatment. Pneumonia is the commonest precipitant of acute 
respiratory distress syndrome (ARDS) and clinicians should be mindful that the evidence-base surrounding 
ARDS will, in large part, apply to severe pneumonia. The causative organisms which lead to pneumonia vary 
depending on the site of acquisition (community or hospital-acquired), the immune status of the patient and 
the presence of intercurrent medications including antibiotics. Current standard microbiological testing is 
seldom able to give a rapid answer as to which microorganisms is present and causing infection. Therefore, 
empirical therapy guided by knowledge of local microbial flora and resistance patterns is the recommended 
course of action. This approach risks the over-treatment of pneumonia with unnecessarily broad-spectrum 
agents which bring with them the problems of antibiotic-associated harm. Novel rapid diagnostic tests 
aimed at both the pathogen and the host response hold promise in the rationalisation and appropriate 
targeting of antimicrobial therapy. At present neither scoring systems nor diagnostic tests are able to 
accurately risk stratify a patient’s need for intensive care admission. Beyond antibiotic therapy, a number 
of adjuvant therapies have been trialled in pneumonia although none have yet made it into widespread 
clinical use. Corticosteroids are recommended in some cases of community-acquired pneumonia (CAP), 
but their role in the patient with severe CAP in ICU remains uncertain whilst they are a risk factor for the 
development of hospital and ventilator-acquired pneumonia. Immuno-stimulation has not yet translated 
from small scale clinical trials into clinical use. Supportive management includes lung protective ventilation, 
and those interventions proven to improve outcomes in ARDS. This review will give an overview of the 
epidemiology of severe pneumonia, the microbiological causes and diagnostic strategies. It will then turn to 
management, including antimicrobial therapy, role of adjuvant therapies, respiratory support and prevention 
of complications. 
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Introduction
Pneumonia is an inflammation of the alveolar airspace, 
most commonly triggered by bacteria but also arising 
from other classes of pathogen and less frequently by 
autoimmune processes. The infiltration of the alveolar 
space by leucocytes and a fibrinous exudate impairs lung 
function, and in its more severe forms can require invasive 
ventilation and admission to an intensive care unit (ICU). 
This review will focus on severe infectious pneumonia and 
its management in the ICU.
There are limited data on the incidence of severe 
pneumonia, although reports from the United States 
suggest nearly 20% of adults hospitalized with pneumonia 
will be admitted to ICU (1), with a clear seasonal pattern 
being evident. However the burden of pneumonia is 
considerably greater in low and middle income countries 
where the critical care resources are considerably less (2). 
Pneumonia is not only a precipitating factor leading to 
admission to ICU, but is also the commonest secondary 
infection acquired by critically ill patients (3). ICU-acquired 
pneumonia is largely ventilator-associated and presents 
specific problems of diagnosis and management (4).
The causative organisms in pneumonia are heavily 
influenced by where patients acquire the disease and the 
condition of their immune system (5), with differences 
in the flora causing community-acquired and hospital-
acquired infections (6). Patients with impaired immune 
function are at risk of opportunistic pathogens such as fungi 
and otherwise ‘low pathogenicity’ bacteria (7), in addition to 
the more classically pathogenic organisms which infect the 
immunologically intact as well. This review will consider 
four broad categories of pneumonia, namely community-
acquired, ventilator-acquired pneumonia, hospital-acquired 
and pneumonia in the immunocompromised host. It will 
also consider the overlap between pneumonia and acute 
respiratory distress syndrome (ARDS) (8).
The greatest  chal lenges  in the Intensive Care 
management of pneumonia are in the diagnosis and 
identification of the causative organisms, the selection 
o f  appropr ia te  ant ib io t i c s  and  de termin ing  the 
duration of therapy, and in the prevention of secondary 
pneumonia. This review will cover the epidemiology of 
severe pneumonia as well as the aetiology and how our 
understanding of microbial ecology is changing the concept 
of infection. It will then turn to diagnosis, considering 
the existing diagnostic strategies and future directions in 
diagnostic technologies, before turning to management 
of both antibiotic and non-antibiotic therapies. Beyond 
antimicrobial therapy, management focuses on supportive 
therapy, protective ventilation and the avoidance of 
complications of ICU admission.
Epidemiology of severe pneumonia
Severe pneumonia lacks a unifying definition, however 
for community-acquired infection the Infectious Diseases 
Society of America/American Thoracic Society (IDSA/
ATS) definition being pneumonia which requires admission 
to an ICU (9,10) is widely used. Although this definition 
concerns community-acquired pneumonia (CAP), it can 
also be extended to hospital-acquired pneumonia and 
pneumonia in the immunocompromised host. Ventilator-
associated pneumonia (VAP), with its attributable mortality 
of 8–10% (11) and its restriction to critically ill patients, can 
be similarly considered ‘severe’. 
ARDS, being defined as respiratory compromise with 
bilateral radiographic infiltrates not fully explained by 
cardiac failure (12), clearly has considerable overlap with the 
diagnosis of severe pneumonia. It is therefore unsurprising 
that pneumonia constitutes around 60% of patients in 
studies of ARDS (8). The evidence which underpins practice 
in ARDS applies to those patients with severe pneumonia 
who meet the criteria for ARDS, and has been reviewed 
recently elsewhere (13) and will be summarised below. 
Amongst patients hospitalized with CAP, up to 20% may 
require admission to ICU (1), although this proportion 
may vary widely by country (14) and by availability of 
ICU beds (15), and shows marked seasonal variability (16). 
Pneumonia is the commonest cause of death in low income 
countries, whilst in upper-middle income and higher 
income countries it is the 6th commonest cause of death and 
the leading infectious cause of death (17). Estimates of the 
mortality rates from European countries show a wide range 
of reported values from <1% to 48% although differences 
in reporting may be responsible for some of this variation. 
From the perspective of an ICU clinician, in England at 
least, pneumonia remains the commonest infectious cause 
of admission, and carries a mortality rate of 35% (18) and in 
international surveys is the commonest infection found in 
ICU patients (19).
Pneumonia is also a frequent complication of hospital 
stay, with hospital-acquired pneumonias (HAP) developing 
in between 1% and 5% of all hospitalized patients (20,21). 
HAP is defined as pneumonia developing at least 48 hours 
after hospital admission, and is generally considered to be 
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‘non-ventilator associated’ as VAP is its own diagnostic 
entity (22). Giuliano and colleagues recently assessed the 
mortality associated with HAP in a large US database (21), 
the crude mortality of 13.1% exceeded that of a population 
matched for illness severity without pneumonia (mortality 
11.2%) and those admitted with CAP (mortality 3.5%), with 
only patients with VAP having a higher mortality (17.5%). 
There is limited data on the rates of admission to ICU for 
HAP. However what data there is suggests that, despite the 
reported mortality, ICU admission may occur in only 3–5% 
of patients developing HAP (23). One of the significant 
difficulties in determining the epidemiology of HAP is the 
frequency with which it is over-diagnosed (20,23), an issue 
we will return to when considering VAP.
To further complicate matters, the entity of ‘healthcare 
associated pneumonia’ or HCAP had been proposed by the 
Infectious Diseases Society of America/American Thoracic 
Society (IDSA/ATS) (22), as a an infection developing 
in someone with close healthcare contact such as recent 
hospital admission, nursing home residence or in receipt 
of intravenous antibiotics within the past 30 days (22). It 
was felt that such a definition was required as patients with 
HCAP are thought to be at increased risk of infections 
with multi-drug resistant (MDR) organisms. However 
more recent studies examining the differences in MDR 
rates between CAP and HCAP have indicated that MDR 
organisms are not restricted to HCAP patients and can 
be predicted by individual patient characteristics rather 
than needing to be considered as a separate entity (5,24) 
and HCAP was removed from the most recent IDSA/ATS 
guidelines (25). 
Patients with immunocompromise, be that through 
immunosuppres s i ve  drugs ,  in fec t ion  w i th  HIV, 
haematological malignancy or primary and secondary 
immune deficiency disorders are at risk of infections in 
general and pneumonia specifically. Whilst specific rates of 
infection will vary depending on the cause and severity of 
the immune deficiency, this group are worth highlighting 
because of their susceptibility to opportunistic infections 
such as fungi and parasites, alongside the more conventional 
pneumonia pathogens. This will be discussed further in the 
next section.
The final category of pneumonia which will  be 
considered in this review is VAP, which by its very definition 
is solely confined to the ICU. VAP remains the commonest 
secondary infection to occur in ventilated ICU patients (26), 
despite considerable efforts to reduce and control this disease 
(27,28). VAP affects around 16% of ICU patients (29), 
although as incidence is significantly altered as a function of 
exposure (30) it is usually expressed as incident density (cases 
per 1,000 ventilator days) (31), with quoted rates of 13.6 
cases per 1,000 ventilator days globally (29). The mortality 
associated with VAP is difficult to disentangle from the 
severity of the underlying illness, however the most rigorous 
estimates indicate that VAP incurs an additional mortality 
burden of 6–10% (30,32).
Microbiology of severe pneumonia
The microbial pathogens which cause pneumonia 
are influenced by the environmental exposure of the 
patient prior to them developing infection, as well as 
their underlying immune state. The generally accepted 
pathogenesis of bacterial pneumonia involves colonisation 
of the upper respiratory tract by the organism, followed by 
migration to the lower respiratory tract and proliferation 
leading to infection. It remains unclear why some people 
become colonized with pathogenic organisms but do not 
progress to pneumonia, whilst others do, although being 
resistant to colonisation with a specific organism does appear 
to protect against infection from that same organism (33). 
The acquisition of viral pneumonia is likely to differ from 
that of bacterial, in that exposure leads to viral infection 
and proliferation, although again there is a wide range of 
responses to viral infection ranging from resistance, through 
asymptomatic shedding to severe pneumonitis (34).
Across all types of pneumonia, culture-negative infection 
remains the commonest reported state, occurring in around 
65% of CAP patients (35), and up to 70% of patients with 
suspected VAP (36) with similar rates reported for patients 
with HAP (37). Whilst some culture-negative results may 
reflect misdiagnosis, especially in the case of VAP where so 
many conditions may mimic it (38), a significant proportion 
are likely to be due to the imperfect nature of conventional 
microbiology (39). The limitations of current diagnostics 
will be discussed below, but any appreciation of the 
microbial ecology of pneumonia needs to be considered in 
this light.
When an organism is detected in CAP, the dominant 
organism remains Streptococcus pneumoniae, with gram 
negative organisms such as Haemophilus influenzae and 
Moraxella catarrhalis as well as the atypical or intracellular 
organisms (Legionella pneumophilia, Mycoplasma pneumoniae, 
Coxiella burnetii, Chlamydia psittaci). Although there 
is considerable anxiety about community-acquired 
staphylococcal pneumonia, and particularly methicillin 
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resistant Staph. aureus (MRSA), surveillance reports suggest 
that it is rare (40,41).
With the advent of routine use of viral polymerase 
chain reaction (PCR) testing of respiratory samples, viral 
coinfection is increasingly recognised and may comprise 
up to a third of cases presenting to hospital (39). It is 
also now more widely accepted that several respiratory 
viruses, and not just influenza, can cause a widespread 
pneumonitis (42).
The microbiological aetiology of ventilator and hospital-
acquired pneumonia differs somewhat from that seen 
in CAP, with gram-negative organisms being far more 
prevalent alongside Staphylococcus aureus which forms 
the predominant gram-positive organism. Table 1 below 
illustrates the difference.
The microbial aetiology of HAP is similar to VAP (48,49), 
although there is a growing recognition of nosocomial viral 
infections (49), which have mostly been reported in HAP 
rather than VAP (43).
Fungal pneumonia is often considered in patients 
w i th  immunocompromise ,  such  a s  those  t ak ing 
immunosuppressive drugs for autoimmune disease or solid 
organ transplantation (50,51), haematology-oncology 
patients (52) and those with HIV (53), although broad-
spectrum antibiotic use, mechanical ventilation and major 
surgery are also recognised risk factors (50,51). Critically 
ill patients frequently develop immunoparesis during the 
course of their illness (26,54), and fungal pneumonia is 
reported although remains rare in the absence of additional 
causes of immunosuppression such as neutropaenia or use 
of immunosuppressant drugs (43,55).
The reasons for the different microbial aetiology 
of  community and hospital-acquired pneumonias 
may reflect different environmental exposure, as the 
hospital environment is much more likely to contain the 
multi-resistant gram-negative organisms which typify 
Table 1 Proportions of infections arising from different organisms in community-acquired and ventilator-acquired pneumonia
Organism Hospital-acquired Community-acquired
Gram-positive 32% 49%
Staphylococcus aureus 20% (Methecillin resistant 11%) 7%
Coagulase negative Staphylococcus 1% 0.2%
Streptococcus pneumoniae 4% 39%
Other Streptococcus spp. 8% 3%
Gram-negative 65% 36.9%
Enterobacteriaceae 14% 9%
Pseudomonas aeruginosa 24% 4.5%
Haemophilus spp. 10% 19%
Acinetobacter spp. 8% 0.2%
Neisseria spp. 3% 0.2%
Stenotrophomonas maltophilia 2% 0%
Other Gram–negative 4% 4%
‘Atypical’ bacteria 0% 8%
Anaerobes 1% 0.2%
Fungi 1% 0%
Respiratory viruses 0%* 36%
Data drawn from 24 studies of VAP reviewed in Chastre and Fagon (43), and pooled data from 5 studies of community-acquired 
pneumonia (39,44-47). Totals do not sum to 100% as some patients have more than one infecting organism. *, the advent of widespread 
molecular testing since the publication of Chastre and Fagon’s review has revealed more viral involvement in HAP although the true extent 
of these agents as causes of HAP remains unclear.
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HAP/VAP (56). In addition, HAP/VAP tends to occur 
after patients have been exposed to antibiotics, which will 
exert selective pressure on microorganisms and lead to a 
predominantly resistant flora emerging (57). However it is 
also apparent that severe illness itself can induce a change in 
the pulmonary microbiota, with a shift towards enteric-type 
gram negative organisms and a reduction in diversity (58) 
which may be independent of inter-current antibiotic 
therapy (59). Changes in bacterial ingress, elimination 
and growth during acute illness alter the balance of lung 
microbiota (60), and it has been suggested that VAP (and 
possibly HAP) represent more ‘overgrowth’ of pathogenic 
bacteria rather than de-novo acquisition and infection (61). 
A high prevalence of oral commensals such as Mycoplasma 
salivarium has been reported in VAP, and these organisms 
may also drive immune suppression and facilitate further 
infection (62).
Diagnosis of pneumonia in ICU
Pneumonia is defined as inflammation of the airspaces (63), and 
as such the gold standard for diagnosis is histopathological 
examination. However, in the vast majority of cases, lung 
biopsy is neither practical nor desirable in a severely ill 
patient, whilst post-mortem examination is clearly too late 
to alter management. Clinicians are, therefore, required 
to rely on surrogate markers of alveolar inflammation and 
infection which present a degree of uncertainty.
Clinical criteria
The clinical criteria for pneumonia comprise evidence of 
systemic inflammation, such as pyrexia, tachycardia and 
leukocytosis/neutrophilia, combined with localizing chest 
signs such as rales, crepitations and bronchial breathing 
(64,65). These will  frequently be accompanied by 
productive cough and breathlessness. However, clinical 
examination has limited sensitivity and specificity in the 
relatively uncomplicated primary care setting (66). It 
loses further diagnostic performance in Intensive Care 
where examination is restricted, mechanical ventilation 
induces auscultatory artifact (67) and where many 
disease processes may mimic the non-specific findings in 
pneumonia (38).
Given the poor performance of clinical criteria alone, 
these are often combined with radiographic techniques, 
including plain chest X-rays, ultrasound and computed 
tomography.
Radiographic criteria
Radiological investigations in suspected pneumonia aim to 
demonstrate the presence of alveolar inflammation, either 
in the form of lobar/sub-lobar consolidation or diffuse 
alveolitis. The gold standard for radiological examination 
of the lungs is computed tomography (CT), given its ability 
to localize and characterise pulmonary lesions to a much 
greater resolution than plain radiographs (67). However 
CT of the chest requires the patient to be moved off the 
ICU, which increases the risk of adverse events in both 
ventilated and non-ventilated patients (68) and is therefore 
not a routine investigation for ICU patients with suspected 
pneumonia. 
Plain chest radiography (CXR) can be performed at the 
bedside, and is the recommended modality for imaging 
in CAP (9,64). Interestingly, neither the most recent 
European (69) nor American (25) guidelines on Hospital- 
and Ventilator-acquired pneumonia make recommendations 
on radiological investigation of pneumonia, despite the fact 
that nearly all clinical studies of HAP/VAP require presence 
of radiographic infiltrates as an inclusion criteria and both 
European Centre for Disease Control (70) and US Centres 
for Disease Control (71) definitions require radiographic 
demonstration of infiltrates. Amongst ICU clinicians, in the 
UK at least, up to 1/3rd do not think radiographic evidence 
is required to diagnose pneumonia (72). 
Bedside ultrasound may outperform plain radiography 
(67,73) in the detection of consolidation, although lesions 
must be relatively superficial within the lung to be detected. 
To date no guidelines have adopted chest ultrasound as 
a recommended diagnostic modality, and no study has 
demonstrated its use changing outcomes for patients.
Microbiological culture
As noted at the start of this article, pneumonia requires 
the presence of an infectious organism and therefore 
detection of the responsible organism should guide 
treatment. Microbiological cultures are an imperfect 
method of detection, and frequently give rise of false 
negative results (39). In CAP the ATS/IDSA (9) and British 
Thoracic Society (BTS) guidelines (64) recommend routine 
microbiological sampling of sputum and blood in severe 
pneumonia, which will cover all cases admitted to Intensive 
Care, alongside specific antigen testing for Legionella 
pneumophilia and Streptococcus pneumoniae. The use of 
invasive sampling, by bronchoscopy or fine needle aspiration 
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are discussed but not specifically recommended, in part due 
to a lack of systematic examination of the role of invasive 
sampling in CAP, and the generally good performance of 
sputum relative to bronchoalveolar lavage (BAL) when 
theses samples have been compared head to head (74). For 
the intubated patient, endotracheal aspirate (ETA) is a form 
of sputum sample which is less prone to contamination from 
the oropharynx and is the sample most likely to be available 
in ventilated ICU patients. Where BAL may have a role is 
in patients who do not have productive sputum or where 
there is a failure to respond to conventional treatment (74). 
The pre-test probability of pneumonia is higher in patients 
presenting with apparent CAP than VAP, and therefore 
culture or detection of a pathogenic organism is generally 
considered diagnostic without the need for quantitative 
cultures.
In VAP the need for deep respiratory cultures is equally 
strong, and both US and European guidelines recommend 
obtaining samples by ETA and undertaking quantitative 
or semi-quantitative cultures. Debate continues within the 
critical care and infectious disease community regarding 
the role of BAL and protected specimen brush (PSB), being 
more invasive than ETA, in the diagnosis of pneumonia. 
The issues revolve around the rapid and near universal 
colonisation of the trachea and upper bronchial tree within 
a few days of mechanical ventilation (75), and whether the 
benefits of targeting antimicrobial therapy outweigh the 
risks of invasive sampling.  Given the high prevalence of 
upper bronchial colonisation and the lack of specificity of 
clinical features of pneumonia (38), ETA culture is likely to 
significantly overestimate the rate of true pneumonia (76), 
whilst applying high quantitative cut-offs may lead to false 
negative results (76). BAL and quantitative culture has 
therefore become the standard in biological research in 
VAP, where a well-defined clinical phenotype is required 
(77,78). What remains less certain is the benefit in clinical 
practice of invasive sampling, although intuitively directing 
antibiotics only at those patients with proven pneumonia 
seems to be rational approach. 
There have been three randomised trials (79-81) 
investigating the role of invasive sampling on outcomes in 
patients with suspected pneumonia, with divergent results. 
Whilst Solé Violán and colleagues (79), and the Canadian 
Critical Care Trials Group (81) did not show any change 
in mortality, Fagon and colleagues (80) demonstrated a 
significant reduction in mortality. Whilst there may be 
many reasons for these discrepancies, it is notable that only 
Fagon and colleagues demonstrated a significant difference 
in antibiotic use, with the invasive strategy driving a 
substantial increase in antibiotic free days. Observational 
studies do suggest that implementation of invasive strategies 
in ICU can drive reduction in the use of antibiotics (76,82), 
and that stopping antibiotics in culture negative patients 
leads to fewer MDR infections without an increase in 
mortality (83).
In hospital-acquired pneumonia optimal diagnostic 
strategy remains uncertain, but obtaining good-quality 
respiratory secretions for culture by sputum, ETA or 
BAL is recommended (25). Specific recommendations for 
immunocompromised patients are lacking.
Molecular diagnostics
PCR
Although culture-free microbiological techniques, such 
as antigen testing, have existed for a long time, they are 
limited to single organisms and indeed often specific 
strains or types of those organisms. By contrast there have 
been significant recent developments in the field of PCR 
based diagnostics, which rely on the amplification and 
detection of specific genetic sequences. Selecting species 
or genus specific genetic sequences can allow the rapid 
and sensitive detection of relatively low numbers of gene-
copy numbers (84), indicating the presence of an organism’s 
genetic material. The use of real-time (RT) PCR allows for 
quantitation of gene-copies, which provides an indication of 
the number of organisms present. However, the existence 
of multiple copies of a gene within some organisms means 
that there may not be a direct correlation between the 
PCR quantitation and organism number (85). Although 
clinical PCR for respiratory infections was pioneered in 
the diagnostics of viral infections, there are an increasing 
number of bacterial PCR-based diagnostics on the market 
and this number is likely to grow rapidly over the next 
years.
Multiple single PCR reactions are time consuming 
and expensive, and therefore groups have looked to 
combine them into multiplex reactions (86), although the 
optimisation required for these can be considerable and they 
may be increasingly susceptible to sample-based inhibitors 
and internal control failure (87).
The advantage of molecular techniques is that they do 
not rely on the organism being alive, or capable of division 
and growth. They are therefore less susceptible to the risks 
of false negative results arising from inter-current antibiotic 
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use and have a much higher yield than culture-based 
techniques (39). However, their increased sensitivity runs 
the risk of detecting irrelevant or colonising organisms, 
and DNA from infecting pathogens may persist long after 
active infection has ended, thus these tests may increase 
rather than decrease the burden of antibiotics. Conversely 
the selectivity of these tests may also be a disadvantage, as 
organisms which are not covered by the included sequences 
will not be detected. To date, no study has been reported 
using bacterial or fungal PCR to guide clinical management 
of severe pneumonia.
Sequencing 
An alternative molecular approach to detection of micro-
organisms is to sequence the nucleic acids present and 
then match these against known sequences from databases 
of microbial DNA. The ubiquity of the 16s ribosomal 
RNA gene in every bacteria, with pan-bacterial conserved 
sequences and genus/species specific sequences (88) has 
been exploited to develop unbiased tests for bacteria. To 
date the diagnostic performance of these approaches has 
been disappointing (89), although total burden of 16s DNA 
may act as a useful marker of bacterial load in VAP (90) and 
blood culture (91). Until recently the alternative approach 
of sequencing all base-pairs present in a sample, so called 
metagenomics, has been prohibitively expensive and too 
slow to be of use clinically although it forms the basis of 
many studies of the lung microbiome (58). However the 
development of devices such as the Nanopore device (92) 
may bring this approach to clinical utility soon. As with 
targeted PCR, these highly sensitive approaches risk the 
detection of clinically irrelevant organisms, and their use 
requires careful evaluation in well conducted trials before 
they can be recommended for routine clinical use.
Novel optical techniques
Several novel techniques have been developed for the 
detection of bacteria, including the use of fluorescent 
probes for in-vivo imaging via devices such as the alveolar 
fibroscope developed by Dhaliwal et al. (93). These probes 
may be combined with those for activated neutrophils (93) 
so allowing combined confirmation of alveolar bacterial 
presence and inflammation, the hallmark of pneumonia. 
These devices remain experimental, and they are currently 
someway from clinical use.
Ex-vivo automated microscopy of samples, allowing 
detection of growth of bacteria at much lower numbers 
than required for conventional microbial culture also holds 
promise, allowing for the rapid detection of viable bacteria. 
This approach may provide rapid, sensitive testing whilst 
reducing the risks of detecting irrelevant organisms (94).
Host markers
The second component of pneumonia is the inflammatory 
host response, and this has been the focus of considerable 
research interest over the past couple of decades. 
Biomarkers can be measured in both pulmonary secretions, 
ETA or lavage, or blood.
Although the list of lavage based biomarkers of 
ventilator-acquired pneumonia which have been advanced 
is considerable (95), only one test (based on alveolar 
concentrations of IL-1 and IL-8) has been successfully 
validated (77,78). This test is undergoing evaluation as a 
measure to improve antibiotic stewardship, with the trial 
having been completed and results expected to be published 
soon (96) (NCT01972425).
There has been much less  work on pulmonary 
biomarkers in community-acquired and non-VAP hospital-
acquired pneumonia, and whilst it is likely that the intense 
pulmonary inflammation which accompanies VAP (97) is 
mirrored in these diseases, this remains to be conclusively 
demonstrated.
Circulating host biomarkers such as C-reactive protein 
(CRP) and procalcitonin (PCT) are in routine use as 
monitors for infection in many ICUs, however evidence 
of their diagnostic utility in hospital-acquired pneumonia 
is limited (98,99) and their use for this purpose is not 
recommended in guidelines (25,69). By contrast, there is 
some evidence of utility of CRP in community acquired 
pneumonia (100) and BTS guidelines suggest it can be used 
to discriminate between pneumonia and non-pneumonic 
processes (64), whilst the IDSA/ATS guidelines remain 
silent on the issue (9). This divergence between HAP/VAP 
and CAP will likely reflect the differing pre-test probability 
of pneumonia seen in patients presenting with a de-novo 
infection and those developing secondary complications in 
hospital. Where PCT may have a role is in the guidance of 
de-escalation and early discontinuation of antibiotics, with 
this being studied in critically ill patients with pneumonia 
being the predominant diagnosis (101). However, patients in 
the standard management arms of PCT studies tend to have 
prolonged courses of antibiotics, in the PRORATA study 
median duration of antibiotic therapy was 13 days whilst 
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in the PCT group it was 10 days (102), both of which may be 
longer than is required to treat most pneumonias (see below). 
By contrast in De Jong’s recent study, median antibiotic 
duration was reduced from 7 to 5 days, with a significant and 
persistent mortality benefit in the PCT group (101). 
Severity scoring and determining which patients 
require admission to ICU
There are a number of pneumonia severity scores, which 
use a range of clinical, demographic and laboratory 
parameters to score patients and assign a severity band 
to them. This work has come almost entirely from the 
CAP literature, which is unsurprising as these patients 
will present to a range of settings from primary care to 
emergency departments and there is a need to identify 
those requiring hospital admissions. Patients with CAP 
who are ventilated immediately have a mortality of 24%, 
but those who deteriorate at a later time point have a 
mortality of 49% (14). Although it is unclear to what extent 
this mortality difference was due to delays in care and to 
what extent it was due to different disease trajectories, 
early admission to ICU for patients with markers of severe 
pneumonia appears prudent. 
The two most commonly used pneumonia severity 
scores, the Pneumonia Severity Index (PSI) (103) and 
CURB-65 scores (104) are both well validated predictors 
of mortality at 30 days. However their ability to predict 
ICU admission or requirement for mechanical ventilation is 
moderate at best (105), as are the severe pneumonia criteria 
set out by in the ATS/IDSA guidelines (9). A significant 
proportion of patients with pneumonia die without being 
admitted to ICU, due to treatment limitation decisions and 
comorbidities, and therefore it is perhaps unsurprising that 
predictors of 30 day mortality may not correspond well 
with need for ICU admission (10). Kolditz and colleagues 
identified a number of readily determinable factors which 
predicted ICU admission, including focal chest signs at 
presentation, multilobar involvement on CXR, comorbid 
conditions especially home oxygen requirement and 
physiological instability (14). However, these criteria have 
not yet been validated in an external cohort, and neither has 
a specific score nor criteria been developed.
Management of pneumonia in ICU—
antimicrobials
The corner stone of pneumonia management is the 
administration of appropriate antibiotics in a timely fashion. 
Delay, and especially administration of antibiotics which do 
not cover the infecting organism are associated with adverse 
outcomes including increased mortality and prolonged 
length of stay (106). However, given the problems outlined 
in the microbiological diagnosis of pneumonia above, 
the infecting organism is almost never known at the time 
of illness onset and clinicians must use empiric therapy 
targeted at likely organisms. This approach leads to early 
use of broad-spectrum antibiotics, especially in patients who 
are high risk of MDR infection such as those with VAP, 
HAP, and immunocompromised patients. Once the results 
of microbiological cultures are known, antibiotics should 
be adjusted and where appropriate deescalated (9,25,64,69), 
however this occurs variably in practice (107).
Antibiotic selection should be informed by the local 
antibiogram, combining data on the prevalent organisms 
and their likely resistance patterns. Updating the local 
antibiogram is an important wider societal reason for 
obtaining microbiological cultures in patients with 
pneumonia. Given the empiric nature of therapy, it is 
important to recognise the differences in organism and 
resistance patterns depending on location of acquisition and 
risk factors for MDR bacteria (see epidemiology section 
above). In CAP, empiric therapy is mostly aimed at gram-
positive organisms, specifically Streptococcus pneumoniae, and 
generally low-resistance gram-negative organisms such as 
Haemophilus influenzae alongside ‘atypical’ bacteria. Although 
specific recommended antibiotics will vary by national 
availability and local antibiogram, a beta-lactam antibiotic 
with beta-lactamase resistance or combined with a beta-
lactamase inhibitor such as co-amoxiclav or a 2nd generation 
cephalosporin are advised (6,64). The addition of a macrolide 
to empiric therapy for CAP is strongly recommended (9,64) 
and is associated with a reduction in mortality (108). It is 
unclear if this benefit is solely due to coverage of hard-to-
detect atypical organisms, or if the immunomodulatory 
effects of macrolides are also important (109).
In patients who are at greater risk of MDR bacteria 
empiric therapy needs to cover these organisms, often 
including Pseudomonas and methicillin resistant Staphylococcus 
aureus (MRSA). These two organisms in particular pose 
a problem as they are frequently resistant to most front-
line antibiotics, and their treatment can involve antibiotics 
such as aminoglycosides and glycopeptides, which have an 
unfavourable toxicity profile (110). Empiric therapy runs 
the risk of over-treatment and thus increases the risk of 
toxic side effects. Therefore, patients need to be assessed for 
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their risk of harbouring these particularly difficult to treat 
organisms prior to initiating treatment. Risk factors for 
Pseudomonas and MRSA include prior intravenous antibiotic 
use, previous culture of these organisms from a colonising 
or infecting site and recent hospitalisation of >5 days. 
The problem is that these risk factors describe many of 
the patients who develop VAP and HAP. The use of dual 
antibiotic therapy vs monotherapy in HAP and VAP has 
been examined in several trials (111-113) and a meta-
analysis (114). These suggest that, in populations with a 
moderate rate of pseudomonas infection (14%), no benefit 
to dual therapy (114). Observational studies, which examine 
patients with high disease severity, who are often excluded 
from clinical trials, suggest that patients with septic 
shock may benefit from dual therapy (115). As a result 
the European guidelines for HAP and VAP advocate dual 
therapy for patients with high disease severity (69) whilst 
IDSA/ATS guidelines advocate dual therapy for those 
with risk factors for resistant Pseudomonas or MRSA (25). 
However, the findings of Kett and colleagues sound a note 
of caution over this advice, they observed that patients with 
HAP treated with IDSA/ATS compliant dual antibiotic 
therapy had a higher mortality than those treated with 
monotherapy (116). For patients with, or at risk of, extended 
spectrum beta-lactamase secreting organisms, carbapenems 
appear to be superior to piperacillin-tazobactam (117). 
Although this data comes from blood stream infections 
mostly arising from urinary and intraabdominal sources, it 
seems reasonable to apply it to pneumonias at present. In 
both CAP and HAP/VAP it is likely that the development 
and widespread adoption of rapid diagnostics will lead to 
more targeted therapy and will allow more precise trialling 
of antibiotic strategies.
Nebulised antibiotics are used in the management of 
MDR bacteria in several contexts, and is supported by 
the American guidelines on HAP and VAP (25), however 
this is based on weak evidence and many units do not use 
nebulised antibiotics at all (118). Where they are used, 
practice is variable and seldom in accordance with the 
advised best practice (118). Before this approach achieves 
widespread adoption, well conducted trials are needed.
The optimal duration of antibiotic therapy in pneumonia 
remains uncertain. There have been several trials which 
have examined fixed duration treatments (119-121), which 
have been analysed in systematic reviews (122). These 
trials compared ‘short’ (7–8 days) with long (10–15 days) 
of therapy, and in meta-analysis there was no benefit to 
prolonged treatment in terms of mortality, cure rate or 
recurrence, whilst prolonged therapy was associated with 
increased risk of subsequent MDR infection. As these 
studies excluded patients with lung abscesses and collections, 
empyema, necrotising pneumonia and bronchiectasis/
cystic fibrosis, this approach cannot be extrapolated to 
these patients. Concern about possible recurrence of 
Pseudomonal, and other non-fermenting gram-negative 
organism, infection with short course antibiotics (119) has 
led to a recommendation that patients with these infections 
should have 14 days of therapy (25,69). Fixed duration 
antibiotic therapy applies fairly arbitrary time-scales to 
patients and fails to account for individual variation. There 
is now reasonable evidence that ‘low risk’ patients, as 
determined by falling CPIS scores or falling PCT levels 
can have their antibiotics stopped at shorter time points, 
without harm and with some evidence of benefit (101,123), 
so allowing more individualised therapy. Conversely, if 
a patient is failing to improve a reassessment of needs to 
occur, looking for incorrect diagnosis (for instance missing 
a non-infective inflammatory process), resistant organisms, 
inappropriate therapy, super-infection or the development 
of collections, empyema and lung abscesses.
Management of pneumonia
Adjunctive therapy
Beyond antibiotic therapy, a number of adjuvant therapies 
have been trialled in pneumonia although none have a 
proven role in critically ill patients in ICU (124).
There is some evidence that corticosteroids may enhance 
recovery in CAP and reduce mortality (125,126), however 
these trials enrolled very few patients who were in ICU or 
required mechanical ventilation. Concerns have been raised 
about the use of steroids to treat severe CAP in ICU (127), 
with the few observational studies which focus on this group 
suggesting steroids are associated with a prolonged length 
of stay (128) and increased mortality (129). In patients with 
A/H1N1 pandemic influenza, use of steroids was associated 
with increased mortality and an increase rate of subsequent 
HAP (130). Hopefully the forthcoming CAPE-COD study 
of corticosteroids in critically ill patients with CAP will 
shed more light on this area (NCT02517489). With the 
exception of those developing vasopressor resistant septic 
shock (131), there appears to be no place for the use of 
steroids in the management of HAP and VAP. In patients 
with HIV who develop Pneumocystis jirovecii pneumonia 
steroids have been demonstrated to improve outcomes (132), 
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however this is not proven in patients with PCP without 
HIV and their use in other immunocompromised patients 
without proven PCP is controversial (133). 
Other investigators have adopted an alternative approach 
of immuno-stimulation in pneumonia, acknowledging the 
evidence of immune cell failure in both early and late sepsis 
(26,134). To date immuno-stimulation has been attempted 
without determining patients’ functional immune status, 
the failure to appropriately target therapy may explain the 
negative results from trials of G-CSF in pneumonia (135). 
Alternative strategies such as GM-CSF (136) and interferon 
gamma (137) are under investigation but no large 
randomised trials have yet been published (124). Augmented 
passive immunity is another strategy which shows promise 
is early work, although here human trials are awaited (138).
Ventilation
The need for respiratory support is the commonest reason 
for patients with pneumonia to be admitted to ICU (14). 
There are a growing range of respiratory support options, 
from simple oxygen therapy, through high flow humidified 
oxygen (HFO), non-invasive ventilation (NIV) and 
continuous positive airway pressure (CPAP) via various 
interface devices to full invasive ventilation. HFO has 
gained considerable popularity in recent years and has in 
certain circumstances demonstrable benefits relative to 
NIV/CPAP. Frat and colleagues demonstrated a reduction 
in intubation rates in patients with more severe respiratory 
failure and a decreased 90-day mortality compared to 
simple oxygen therapy and NIV (139), the majority of 
patients in this study presented with pneumonia. More 
recently however, in patients with immunocompromise and 
respiratory failure, HFO did not reduce intubation rates or 
mortality relative to simple oxygen therapy (140). Whilst 
NIV has a proven role in the management of exacerbations 
of chronic obstructive pulmonary disease (COPD) (141), 
its role in pneumonia including pneumonic exacerbations 
of COPD is largely restricted to rescue therapy pending 
mechanical ventilation (64) and intubation should not be 
delayed by the use of NIV (142).
In patients requiring invasive ventilation, the optimal 
mode of ventilation remains to be determined. As noted 
above, pneumonia is the commonest cause of ARDS (8), 
and as ARDS is frequently missed (8,13), care should be 
taken to look for this syndrome in patients admitted with or 
developing severe pneumonia. Patients who meet the criteria 
for moderate to severe ARDS should be managed with low 
volume (6 mL/kg predicted body weight) tidal ventilation 
and limited plateau pressures (143). Adjunctive therapy 
such as muscle relaxation (144) and early proning (145) 
are also indicated for those meeting severe ARDS criteria. 
Care should be taken to avoid fluid overload in patients 
with severe pneumonia (146), and consideration given to 
de-resuscitation and trying to minimise extra-vascular lung 
water (147). For patients who don’t meet moderate to severe 
ARDS criteria the evidence is less clear, a recent trial from 
Schultz and colleagues demonstrated no benefit of low tidal 
volumes relative to moderate (8–10 mL/kg PBW) in patients 
without ARDS (148), however, this study included less than 
20% patients with pneumonia. It remains unclear whether 
patients who are at higher risk of developing ARDS will 
benefit from low rather than moderate tidal ventilation (149).
Management—prevention of secondary 
complications
Patients with severe pneumonia in ICU are at risk of 
the complications of critical care, including deep venous 
thrombosis (150), stress ulceration (151), decubitus 
ulcers (152), delirium (153) and secondary infections (19). 
Careful attention to the risk factor management, 
appropriate prophylactic therapies and alertness to 
the development of these complications is key to good 
clinical management. Patients who present with a primary 
pneumonia, whether it is community or hospital-acquired, 
are at high risk of subsequent nosocomial infections, 
especially if ventilated (30). The various preventative 
measures for VAP have been reviewed extensively 
elsewhere (154), their implementation can lead to a 
reduction in VAP incidence, reduction in antibiotic 
use and mortality in longer staying patients (27). The 
reduction in antibiotic use is likely to drive a virtuous 
circle, reducing colonisation with MDR bacteria and 
subsequent infections with these hard to treat organisms.
Conclusions
Pneumonia remains both a common reason for intensive 
care admission and the commonest secondary infection 
acquired within intensive care. Its effective management 
relies on the selection of appropriate antimicrobial therapy, 
which at present is reliant on good epidemiological 
surveillance to inform empirical antibiotic choice. 
Identifying patients with risk factors for MDR organisms 
is critical to ensuring early, appropriate therapy. Diagnostic 
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uncertainty, especially with regards to VAP, likely leads 
to over-use of antibiotics and brings with it the risk of 
antibiotic-associated harm. The advent of rapid diagnostic 
strategies brings the promise of targeted, appropriate 
therapy and reduction in unnecessary drugs. For this 
promise to be realised we will need to change our culture 
of prescribing and understanding of microbiological tests 
results in a clinical context. 
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